What is Upstream Bio, Inc.'s market cap?

Upstream Bio, Inc. (UPB) has a market capitalization of $425.0M and trades on XNAS.

What is Upstream Bio, Inc.'s revenue and profitability?

Upstream Bio, Inc. generated $3.3M in trailing twelve-month revenue with a net loss of $156.8M, representing a net margin of -4719.0%. These figures are based on the Q1 2026 filing.

Who are Upstream Bio, Inc.'s competitors?

Upstream Bio, Inc.'s key competitors include Regeneron Pharmaceuticals, Inc., Amgen Inc., AstraZeneca PLC, and others. These companies compete in similar markets and product categories.

Who does Upstream Bio, Inc. partner with?

Upstream Bio, Inc.'s notable partners include Astellas Pharma Inc., Regeneron Pharmaceuticals, Inc., Maruho Co., Ltd., and others.

Where is Upstream Bio, Inc. headquartered?

Upstream Bio, Inc. is headquartered in United States of America. It has been publicly traded since 2024.

Upstream Bio, Inc.

UPB

Upstream Bio is a clinical-stage biotechnology company focused on developing novel therapies for inflammatory diseases, with a primary emphasis on severe respiratory disorders.

Market cap

$425.02M-33.3%

Revenue$3.3M+44.7%

Net income-$156.8M-98.0%

EPS (diluted)-$2.90+84.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 13, 2026

Revenue$1.0MBeat by $6.3K EPS-$0.75Miss by $0.01

Read the full report

Next report

Aug 5, 2026 (In 3 weeks)

Revenue estimate$431.1K

EPS estimate-$0.78

Financials

Q1 2026

Income statement

See full

Revenue$1.0M+82.7%

Operating income-$43.6M-36.2%

Net income-$40.6M-48.8%

EPS (diluted)-$0.75-47.1%

Balance sheet

See full

Cash & equivalents$96.7M+35.6%

Total debt$1.1M-34.5%

Total equity$304.0M-31.8%

Total assets$318.1M-30.3%

Cash flow

See full

Operating cash flow-$47.9M-16.2%

Valuation & ratios

Valuation

See full

Market cap$425.02M-33.3%

Enterprise value$329.41M-39.8%

P/S127.9×-89.0×

Profitability

See full

Operating margin-5,176.5%+1,764pp

Net margin-4,719%+2,752pp

Returns & leverage

See full

Return on equity-41.8%—

Debt / equity0×0.0×

Current ratio23.1×-24.3×

Competitors

By market cap

Amgen$196.25B+24.6%

Regeneron Pharmaceuticals$70.0B+20.5%

Kymera Therapeutics$9.8B+218%

AnaptysBio, Inc.$2.0B+186%

Savara$1.3B+219%

Shattuck Labs, Inc.$671.4M+1,716%

Upstream Bio, Inc.$425.0M-28.0%

Edesa Biotech, Inc.$67.6M+367%

By revenue growth

AnaptysBio, Inc.+108%

Upstream Bio, Inc.+44.7%

Amgen+9.1%

Regeneron Pharmaceuticals+5.9%

Kymera Therapeutics-12.6%

Shattuck Labs, Inc.-78.3%

By net margin

Regeneron Pharmaceuticals29.65%-2.3pp

Amgen20.96%+3.6pp

AnaptysBio, Inc.-49.94%+80.0pp

Kymera Therapeutics-611.96%-203pp

Upstream Bio, Inc.-4,718.96%-1,270pp

Shattuck Labs, Inc.-4,987.4%-3,454pp

Savara-19,305.06%—

Profile

Upstream Bio is a clinical-stage biotechnology company focused on developing novel therapies for inflammatory diseases, with a primary emphasis on severe respiratory disorders. The company's lead product candidate, verekitug, is a monoclonal antibody designed to inhibit the Thymic Stromal Lymphopoietin (TSLP) receptor, a validated upstream driver of inflammatory responses. By targeting the receptor rather than the ligand, the company aims to provide a differentiated treatment profile with improved clinical outcomes and significantly extended dosing intervals.

Competitive position

Clinical-stage developer of the only known TSLP receptor antagonist currently in clinical development, positioning it as a potential best-in-class alternative to existing ligand-targeting biologics.

GeographiesUnited States, Japan, Europe

Customer segmentsPatients, Healthcare Providers

Business modelBiotechnology R&D, IP Licensing

SuppliersContract Development and Manufacturing Organizations (CDMOs), Clinical Research Organizations (CROs), Specialized raw material suppliers

CustomersSpecialty pharmacies, Hospitals, Government healthcare programs, Private health insurers

CountryUnited States of America

Listed2024

CEOE. Rand Sutherland

SectorPHARMACEUTICAL PREPARATIONS

IndustryPHARMACEUTICAL PREPARATIONS

Websiteupstreambio.com

FilingsSEC EDGAR

Ask your AI about Upstream Bio, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Upstream Bio, Inc.'s market cap?: Upstream Bio, Inc. (UPB) has a market capitalization of $425.0M and trades on XNAS.
What is Upstream Bio, Inc.'s revenue and profitability?: Upstream Bio, Inc. generated $3.3M in trailing twelve-month revenue with a net loss of $156.8M, representing a net margin of -4719.0%. These figures are based on the Q1 2026 filing.
Who are Upstream Bio, Inc.'s competitors?: Upstream Bio, Inc.'s key competitors include Regeneron Pharmaceuticals, Inc., Amgen Inc., AstraZeneca PLC, and others. These companies compete in similar markets and product categories.
Who does Upstream Bio, Inc. partner with?: Upstream Bio, Inc.'s notable partners include Astellas Pharma Inc., Regeneron Pharmaceuticals, Inc., Maruho Co., Ltd., and others.
Where is Upstream Bio, Inc. headquartered?: Upstream Bio, Inc. is headquartered in United States of America. It has been publicly traded since 2024.